WHO WE ARE
Redefining what’s possible in cancer therapy
At Sutro, we are advancing a cutting-edge, next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, our cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, we aim to overcome treatment resistance and redefine what’s possible in cancer therapy. Our pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies.
Behind every design decision we make is a patient waiting for a better option. By engineering and optimizing every component of our ADCs, our goal is to deliver medicines that are more effective and safer for people living with cancer.